The Anunnaki Creation of Eve and the Alien Battle for Humanity
Chris Hardys new book is an in-depth study of humanity #39;s Anunnaki origins and the Anunnaki battle for an intelligent versus enslaved humanity Explains the genetic engineering of humanity...

By: DisclosureNation

View original post here:
The Anunnaki Creation of Eve and the Alien Battle for Humanity - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

24-Jun-2014

Contact: Press Office news.office@admin.ox.ac.uk 44-186-528-0530 University of Oxford

Computer analysis of photographs could help doctors diagnose which condition a child with a rare genetic disorder has, say Oxford University researchers.

The researchers, funded in part by the Medical Research Council (MRC), have come up with a computer programme that recognises facial features in photographs; looks for similarities with facial structures for various conditions, such as Down's syndrome, Angelman syndrome, or Progeria; and returns possible matches ranked by likelihood.

Using the latest in computer vision and machine learning, the algorithm increasingly learns what facial features to pay attention to and what to ignore from a growing bank of photographs of people diagnosed with different syndromes.

The researchers report their findings in the journal eLife. The study was funded by the MRC, the Wellcome Trust, the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) and the European Research Council (ERC VisRec).

While genetic disorders are each individually rare, collectively these conditions are thought to affect one person in 17. Of these, a third may have symptoms that greatly reduce quality of life. However, most people fail to receive a genetic diagnosis.

'A diagnosis of a rare genetic disorder can be a very important step. It can provide parents with some certainty and help with genetic counselling on risks for other children or how likely a condition is to be passed on,' says lead researcher Dr Christoffer Nellker of the MRC Functional Genomics Unit at the University of Oxford. 'A diagnosis can also improve estimates of how the disease might progress, or show which symptoms are caused by the genetic disorder and which are caused by other clinical issues that can be treated.'

The team of researchers at the University of Oxford included first author Quentin Ferry, a DPhil research student, and Professor Andrew Zisserman of the Department of Engineering Science, who brought expertise in computer vision and machine learning.

View original post here:
Computer-aided diagnosis of rare genetic disorders from family snaps

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

23-Jun-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

Focal therapy for prostate cancer, in which only the tumor tissue is treated with cryoablation (freezing), can prolong life, result in less complications such as incontinence, and improve post-treatment quality of life. But the long-term effectiveness of focal treatments has not been well-studied. A new analysis that followed patients treated with optimized cryoablation of prostate cancer for an average of 10 years post-treatment is published in Journal of Men's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Men's Health website.

In the article "Long-Term Results Of Optimized Focal Therapy Of Prostate Cancer: Average 10-Year Follow-Up in 70 Patients," Gary Onik, MD, Carnegie Mellon University (Fort Lauderdale, FL), and coauthors found that long-term cancer control with focal cryoablation therapy was superior to radical whole gland treatments in patients at medium or high risk for disease-free survival.

###

About the Journal

Journal of Men's Health is the premier peer-reviewed journal published quarterly in print and online that covers all aspects of men's health across the lifespan. The Journal publishes cutting-edge advances in a wide range of diseases and conditions, including diagnostic procedures, therapeutic management strategies, and innovative clinical research in gender-based biology to ensure optimal patient care. The Journal addresses disparities in health and life expectancy between men and women; increased risk factors such as smoking, alcohol abuse, and obesity; higher prevalence of diseases such as heart disease and cancer; and health care in underserved and minority populations. Journal of Men's Health meets the critical imperative for improving the health of men around the globe and ensuring better patient outcomes. Tables of content and a sample issue can be viewed on the Journal of Men's Health website.

About the Societies

Journal of Men's Health is the official journal of the International Society of Men's Health (ISMH), American Society for Men's Health, Men's Health Society of India, and Foundation for Men's Health. The ISMH is an international, multidisciplinary, worldwide organization, dedicated to the rapidly growing field of gender-specific men's health.

Originally posted here:
Is focal treatment for prostate cancer as effective in the long-term as radical therapies?

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

20-Jun-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, June 20, 2014Spiral ganglion cells are essential for hearing and their irreversible degeneration in the inner ear is common in most types of hearing loss. Adult spiral ganglion cells are not able to regenerate. However, new evidence in a mouse model shows that spiral ganglion stem cells present in the inner ear are capable of self-renewal and can be grown and induced to differentiate into mature spiral ganglion cells as well as neurons and glial cells, as described in an article in BioResearch Open Access, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the BioResearch Open Access website.

Marc Diensthuber and coauthors from Goethe-University (Frankfurt, Germany), Justus-Liebig University (Giessen, Germany), Harvard Medical School and Massachusetts Eye and Ear Infirmary (Boston, MA), and Harvard University and MIT (Cambridge, MA), conclude that the self-renewing properties demonstrated by spiral ganglion stem cells make them a promising source of replacement cells for therapies designed to regenerate the neural structures of the inner ear in the article "Spiral Ganglion Stem Cells Can Be Propagated and Differentiated Into Neurons and Glia."

"These findings are particularly interesting as they show that spiral ganglion stem cells can be propagated in vitro," says BioResearch Open Access Editor Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland. "These cells are normally poorly regenerated in the mammalian ear."

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Chief Scientific Officer, Advanced Cell Technology, Inc. and Editor Jane Taylor, PhD. The Journal provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMed Central. All journal content is available on the BioResearch Open Access website.

About the Publisher

Read more here:
Inner ear stem cells hold promise for restoring hearing

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

24-Jun-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, June 24, 2014Frederic D. Bushman, PhD's (University of Pennsylvania Perelman School of Medicine) early pioneering work in understanding how HIV reproduces by inserting its genetic material into the DNA of a host cell led to key advances in the ability to move pieces of DNA and whole genes between cells. In recognition of his scientific achievements and leadership in the field, Dr. Bushman is the recipient of a Pioneer Award from Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Human Gene Therapy is commemorating its 25th anniversary by bestowing this honor on the leading 12 Pioneers in the field of cell and gene therapy selected by a blue ribbon panel* and publishing a Pioneer Perspective by each of the award recipients. The Perspective by Dr. Bushman is available on the Human Gene Therapy website.

In "Engineering the Human Genome: Reflections on the Beginning," Dr. Bushman recalls his research as a graduate student and postdoctoral fellow studying the regulatory mechanisms that control gene expression and identifying DNA binding proteins that virusessuch as the HIV retrovirususe to integrate into a host genome at targeted sites. Currently, retroviral delivery vectors are widely used for gene transfer in Human Gene Therapy. Dr. Bushman's research accomplishments have contributed to the development of new gene delivery vectors and to more effective and efficient methods of targeting them to integration sites, and have advanced the field of gene therapy.

"Rick's background in HIV biology was very useful in his current studies of retroviral and lentiviral vector integration," says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia. "He brought to the field an incredibly sophisticated approach to assess integration sites, which has informed safety profiles."

###

*The blue ribbon panel of leaders in cell and gene therapy, led by Chair Mary Collins, PhD, MRC Centre for Medical Molecular Virology, University College London selected the Pioneer Award recipients. The Award Selection Committee selected scientists that had devoted much of their careers to cell and gene therapy research and had made a seminal contribution to the field--defined as a basic science or clinical advance that greatly influenced progress in translational research.

About the Journal

Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its sister journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of content for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.

View original post here:
Frederic Bushman, Ph.D. receives Pioneer Award for advancing therapeutic gene delivery methods

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

19-Jun-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, June 19, 2014Plasminogen activators are proteins involved in the breakdown of blood clots, and an elevated level of plasminogen activator inhibitor-1 (PAI-1) is associated with an increased risk for clotting and cardiovascular disease. No PAI-1 inhibitors are currently available for clinical use, but a novel therapeutic approach using a targeted RNA aptamer drug that has been shown to block PAI-1 activity and prevent PAI-1-associated vascular events is described in Nucleic Acid Therapeutics, a peer-reviewed journal from Nucleic Acid Therapeutics. The article is available free on the Nucleic Acid Therapeutics website.

Jared Damare, Stephanie Brandal, and Yolanda Fortenberry, Johns Hopkins University School of Medicine, Baltimore, MD, designed a library of small RNA molecules that target different regions of PAI-1. They then screened the library and enriched for the aptamers that were the most selective for binding to and inhibiting the function of PAI-1. The authors demonstrate the ability of these RNA aptamers to prevent PAI-1 from interacting with plasminogen activators in the article "Inhibition of PAI-1 Antiproteolytic Activity Against tPA by RNA Aptamers."

"Even beyond the admirable care and rigor of the work, the therapeutic significance lies in the authors addressing a vital concern: the identification of an aptamer that can specifically disrupt the target function of PAI-1 without inhibiting its other functions," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.

Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Graham C. Parker, PhD.

###

About the Journal

Nucleic Acid Therapeutics is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. Nucleic Acid Therapeutics is the official journal of the Oligonucleotide Therapeutics Society. A complete table of contents and free sample issue may be viewed on the Nucleic Acid Therapeutics website.

Read more here:
RNA aptamers targeted to plasminogen activator inhibitor

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

19-Jun-2014

Contact: Sophie Mohin Smohin@liebertpub.com 914-740-2254 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, June 19, 2014An innovative system using automated 3D printing technology and advanced digital tools to create customized, prefabricated ceramic building blocks, called PolyBricks, is enabling the construction of mortar-less brick building assemblies at much greater scales than was previously possible. The new techniques that use 3D printers to produce modular ceramic bricks from a single material that then interlock and assemble easily into larger units for architectural applications are described in an article in 3D Printing and Additive Manufacturing (3DP), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free online on the 3D Printing and Additive Manufacturing website.

Jenny Sabin, Martin Miller, Nicholas Cassab, and Andrew Lucia, of Sabin Design Lab, Cornell University (Ithaca, NY) and Jenny Sabin Studio (Philadelphia, PA), provide a detailed description of the computational design techniques they developed for the digital fabrication and production of ceramic PolyBrick components. The authors explain how they used available 3D printing technology to produce mass customized components in the article PolyBrick: Variegated Additive Ceramic Component Manufacturing (ACCM)"

"This work offers an exciting new alternative approach for 3D printing at architectural scales, without requiring the large infrastructure that most current methods require. It could open the door to many new applications" says Editor-in-Chief Hod Lipson, PhD, Director of Cornell University's Creative Machines Lab at the Sibley School of Mechanical and Aerospace Engineering, Ithaca, NY.

###

About the Journal

3D Printing and Additive Manufacturing (3DP) is a peer-reviewed journal published quarterly in print and online. The Journal facilitates and supports the efforts of engineers, software developers, architects, lawyers, Deans and academic chairpersons of engineering and business schools, technology transfer specialists, chief research officers and vice presidents of research in government, industry, and academia, medical professionals, venture capitalists, and entrepreneurs. Spanning a broad array of disciplines focusing on novel 3D printing and rapid prototyping technologies, policies, and innovations, the Journal brings together the community to address the challenges and discover new breakthroughs and trends living within this groundbreaking technology. Complete tables of content and a sample issue may be viewed at the 3D Printing and Additive Manufacturing (3DP) website.

About the Publisher

The rest is here:
New digital fabrication technique creates interlocking 3D-printed ceramic PolyBricks

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

19-Jun-2014

Contact: Katie Delach katie.delach@uphs.upenn.edu 215-349-5964 University of Pennsylvania School of Medicine

PHILADELPHIA Autoimmune disease occurs when the body's own natural defense system rebels against itself. One example is pemphigus vulgaris (PV), a blistering skin disease in which autoantibodies attack desmoglein 3 (Dsg3), the protein that binds together skin cells. Left untreated, PV can be fatal, as skin layers slough off and leave the body vulnerable to dehydration and infection. Researchers from the Perelman School of Medicine at the University of Pennsylvania recently found a shared genetic link in the autoimmune response among PV patients that provides important new clues about how autoantibodies in PV originate. Full results of the new study are available today in Nature Communications.

To better understand the nature of the immune response in PV, the researchers cloned anti-Dsg3 monoclonal autoantibodies (mAbs) from four unrelated PV patients. In characterizing the mAbs, they identified a particular gene, VH1-46, that was used by PV antibodies across all four patients.

"This was a very striking finding, because the common gene suggests common mechanisms for developing the disease," said senior author Aimee Payne, MD, PhD, the Albert M. Kligman Assistant Professor of Dermatology at Penn Medicine. "Most people have common antibody gene responses to infections and vaccinations, so when we first started these studies, we suspected this might be the case for PV, we just didn't know which gene it was going to be."

To investigate further, the team set out to determine the nature and frequency of mutations in the complementarity determining regions (CDRs) of the VH1-46 autoantibodies. CDRs are the parts of the antibody that determine its specific antigen target. The researchers found that with very few CDR mutations, or even none at all, VH1-46 mAbs could bind with the Dsg3 protein. This suggests that the inherent tendency of some VH1-46 antibodies to bind Dsg3 could underlie the cascade of events that ultimately lead to PV.

While it's unlikely that the VH1-46 link solves the entire puzzle of PV's origins, it's an important step pointing in the right direction. Payne explains, "We don't think that VH1-46 is everything in PV, because we know that by the time patients show up with full-blown disease, multiple autoantibodies are causing the disease. However, the key is that we find VH1-46 autoantibodies in all of the patients we have studied, which suggests that it may be one of the earliest autoantibodies that appears."

Among the next steps for the research team will be to continue to probe the development of VH1-46 anti-Dsg3 antibodies, specifically whether they cross-react to microbes such as viruses or bacteria. "That could indicate that autoimmunity was mistakenly triggered during the course of an appropriate immune response to infection," says Payne. "Although we don't think this paper is going to immediately affect therapy, we believe that continuing along these lines of study will allow us to better understand how to improve current therapies or develop new strategies to treat disease," she notes. "We're at a really exciting time right now where we have the technologies to be able to address important questions about how PV occurs."

###

Read more:
Penn study reveals a common genetic link in fatal autoimmune skin disease

Recommendation and review posted by Bethany Smith

San Jose, California (PRWEB) June 24, 2014

Follow us on LinkedIn Almost every known disease, ranging from common maladies to life-threatening diseases such as cancer, has a genetic component. Genetic testing represents a rapidly growing branch of molecular diagnostics. Advancements in genetic testing are expected to aid in the development of personalized medicine. Genetic testing, which until recently was confined to specialized medical testing for rare inherited diseases, is forecast to become a standard in healthcare in the coming years. With the advent of advanced DNA analysis, the scope of genetic testing is expanding to include predictive testing (to evaluate susceptibility to common, complex diseases), pharmacogenomic testing (to evaluate varied drug response in different people owing to DNA/RNA changes), and prenatal and newborn testing (to screen for congenital abnormalities). Growing global population in general and aging individuals in particular, present a strong case for genetic testing.

Prenatal testing and newborn testing represents the largest sector of the genetic testing market. With neural tube defects, Downs syndrome, and chromosomal anomalies causing significant increases in healthcare costs, their prevention and management by early genetic testing is gaining significance. Non-Invasive Prenatal Diagnosis (NIPD) market is witnessing rapid growth due to the techniques unrivalled benefits of accuracy, safety, and patient comfort. In developed Western countries, genetic testing of newborns includes enhanced screening panels for a wide range of diseases.

Rising incidence of cancer worldwide is throwing the spotlight on cancer genetic testing. Aging population, lifestyle factors such as alcohol consumption, smoking, and lack of balanced diet and exercise, among others, represent key reasons for the escalating growth in cancer prevalence. Growing awareness over inherited cancer risk is resulting in increased demand for predictive genetic tests for identifying cancer risk genes. Breast cancer gene testing is also on the rise given the global drive towards prevention of the disease.

As stated by the new market research report on Genetic Testing, the United States and Europe constitute the largest markets worldwide. Asia-Pacific ranks as the fastest growing market with a CAGR of over 17% over the analysis period. Growth in the region is led by rising income, implementation of preventive public health policies, and increased government spending on healthcare infrastructure development. Spending in Indonesia, Malaysia, Philippines, and Thailand, is also expected to exhibit impressive double digit growth, due to strong medical insurance systems and the growing trend towards medical tourism.

Key players covered in the report include Abbott Laboratories, Abbott Molecular Inc., AutoGenomics Inc., BioRad Laboratories, ELITech Group SPA, PerkinElmer Inc., Quest Diagnostics Inc., Roche Diagnostics Corp., Roche Molecular Diagnostics Inc., Thermo Fisher Scientific, and Transgenomic Inc., among others.

The research report titled Genetic Testing: A Global Strategic Business Report announced by Global Industry Analysts Inc., provides a comprehensive review of the global market trends, key growth drivers, regulations, market issues and challenges, mergers and acquisitions, agreements and alliances, and other strategic corporate initiatives of global and regional players. The report provides market estimates and projections for all major geographic markets, including the US, Canada, Japan, Europe (France, Germany, Italy, UK, and Rest of Europe), Asia-Pacific, and Rest of World. Product segments analyzed include Prenatal and Newborn Genetic Testing, Pharmacogenomic Testing, and Predictive Testing.

For more details about this comprehensive market research report, please visit http://www.strategyr.com/Genetic_Testing_Market_Report.asp.

About Global Industry Analysts, Inc. Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1500+ full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Global Industry Analysts, Inc. Telephone: 408-528-9966 Fax: 408-528-9977 Email: press(at)StrategyR(dot)com Web Site: http://www.StrategyR.com/

See the article here:
Rising Incidence of Genetic Diseases Drives the Global Genetic Testing Market, According to New Report by Global ...

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

20-Jun-2014

Contact: Daphne Watrin d.watrin@iospress.nl 31-206-883-355 IOS Press

Amsterdam, NL, 20 June 2014 Although significant progress has been made over the last 25 years to identify genetic abnormalities associated with congenital myasthenic syndromes (CMS), many patients remain genetically undiagnosed. A report in the inaugural issue of the Journal of Neuromuscular Diseases identifies a gene defect in mitochondria, specifically the citrate carrier SLC25A1, that may underlie deficits in neuromuscular transmission seen in two siblings.

"While mitochondrial gene defects can cause a myriad of neurological disorders including myopathies and neuropathies, these have not been specifically implicated in defects of the neuromuscular junction," says Hanns Lochmller, MD, Professor of Experimental Myology, Institute of Genetic Medicine, MRC Centre for Neuromuscular Diseases, Newcastle University, Newcastle upon Tyne, UK.

Of the 19 genes that have been implicated in CMS, most express proteins involved in neuromuscular synapse development and function. These mutations usually involve post-synaptic proteins. The current study shifts the area of impairment to the presynaptic region.

Investigators conducted genomic analyses of two patients who are brother and sister. The pair was born to healthy parents who were first cousins. "The family history was highly suggestive of autosomal recessive inheritance," notes Dr. Lochmller. Since childhood, the 33-year-old brother had displayed some speech and motor problems that worsened with exercise and improved with rest. He had mild bilateral ptosis (drooping of the eyelid), speech difficulties, and mild learning disabilities. His 19-year-old sister showed delayed development including recurrent falls, fatigable limb weakness, intermittent double vision, and some drooping of facial muscles.

The investigators performed homozygosity mapping and whole exome sequencing to determine the underlying genetic cause of the siblings' condition and successfully identified a homozygous mutation in the SLC25A1 gene. SLC25A1 is a mitochondrial citrate carrier believed to be a key component in many important biological processes, such as fatty acid and sterol biosynthesis, gluconeogenesis, glycolysis, maintenance of chromosome integrity, and regulation of autophagy.

Using electrophysiologic techniques, researchers were able to show clear abnormalities in the neuromuscular junctions of the patients, as evidenced by increased jitter or jitter with blocking of muscle fibers.

Researchers also found evidence that SLC25A1 may be required for normal neuromuscular junction formation by looking at the effects of reduced expression of SLC25A1 in zebrafish embryos. Anatomically, while the muscle fibers appeared normal, presynaptic motor axon terminals were shortened and grew erratically, with no evidence of complete synapse formation. They also saw structural changes in the brain and heart, which mirrored abnormalities seen in humans.

Read the original:
Researchers identify mitochondrial mutation linked to congenital myasthenic syndrome

Recommendation and review posted by Bethany Smith

Some new genetics
Shout out, and popping some beans.

By: unk40rm

See more here:
Some new genetics - Video

Recommendation and review posted by Bethany Smith

Medical Video Lecture: Chargaff #39;s rules, Genetics
Prepare for USMLE,UK,CANADIAN,AUSTRALIAN, NURSING OTHER MEDICAL BOARD examinations around the globe with us. Understand the basics, concepts and how to answer wisely and score 99 in each...

By: allornonelaw

Read this article:
Medical Video Lecture: Chargaff's rules, Genetics - Video

Recommendation and review posted by Bethany Smith

SNNLive - Atossa Genetics, Inc.
SNNLive met with Dr. Steven Quay, Chairman of the Board and CEO of Atossa Genetics, Inc. (NASDAQ: ATOS) at the Biotech Showcase 2012 in San Francisco, CA. Fo...

By: Stock NewsNow

Continued here:
SNNLive - Atossa Genetics, Inc. - Video

Recommendation and review posted by Bethany Smith

A level. R.7. Cystic fibrosis and gene therapy (Ms Cooper)
What is cystic fibrosis? What systems in the body are affected? What are the symptoms? What is the genotype of someone with cystic fibrosis? What are the different types of treatment? What...

By: Ms Cooper #39;s Cambridge A level Biology

Originally posted here:
A level. R.7. Cystic fibrosis and gene therapy (Ms Cooper) - Video

Recommendation and review posted by Bethany Smith

#AskForMary | Dr. Ho and Mary Free Bed #39;s Spinal Cord Injury Team
Official Website: http://www.maryfreebed.com When choosing a rehabilitation provider, there are many things to consider. Clinical expertise. Technology. Experience. Culture. Mary Free Bed...

By: Mary Free Bed Rehabilitation Hospital

Read more from the original source:
#AskForMary | Dr. Ho and Mary Free Bed's Spinal Cord Injury Team - Video

Recommendation and review posted by sam

Cellus - Start-Up Chile - Round 11
Cellus is a company dedicated to the development of customized products and services for regenerative medicine and anti-aging therapies, delivering effective solutions with a strong biotechnology...

By: Cellus Medicina Regenerativa S.A

See the original post:
Cellus - Start-Up Chile - Round 11 - Video

Recommendation and review posted by sam

Stem cells have the unique ability to become any type of cell in the body. Given this, the possibility that they can be cultured and engineered in the laboratory makes them an attractive option for regenerative medicine. However, some conditions that are commonly used for culturing human stem cells have the potential to introduce contaminants, thus rendering the cells unusable for clinical use. These conditions cannot be avoided, however, as they help maintain the pluripotency of the stem cells.

In a study published in Scientific Reports, a group from the RIKEN Center for Life Science Technologies in Japan has gained new insight into the role of CCL2, a chemokine known to be involved in the immune response, in the enhancement of stem cell pluripotency. In the study, the researchers replaced basic fibroblast growth factor (bFGF), a critical component of human stem cell culture, with CCL2 and studied its effect. The work showed that CCL2 used as a replacement for bFGF activated the JAK/STAT pathway, which is known to be involved in the immune response and maintenance of mouse pluripotent stem cells. In addition, the cells cultured with CCL2 demonstrated a higher tendency of colony attachment, high efficiency of cellular differentiation, and hints of X chromosome reactivation in female cells, all markers of pluripotency.

To understand the global effects of CCL2, the researchers compared the transcriptome of stem cells cultured with CCL2 and those with bFGF. They found that stem cells cultured with CCL2 had higher expression of genes related to the hypoxic response, such as HIF2A (EPAS1). The study opens up avenues for further exploring the relationship between cellular stress, such as hypoxia, and the enhancement of pluripotency in cells. Yuki Hasegawa of CLST, who led the study, says, "Among the differentially expressed genes, we found out that the most significantly differentially expressed ones were those related to hypoxic responses, and hypoxia is known to be important in the progression of tumors and the maintenance of pluripotency. These results could potentially contribute to greater consistency of human induced pluripotent stem cells (iPSCs), which are important both for regenerative medicine and for research into diseases processes."

As a way to apply CCL2 towards the culturing of human iPSCs with more consistent quality, the researchers developed dishes coated with CCL2 and LIF protein beads. This allowed stem cells to be cultured in a feeder-free condition, preventing the risk that viruses or other contaminants could be transmitted to the stem cells. While the exact mechanisms of how CCL2 enhances pluripotency has yet to be elucidated, this work highlights the usefulness of CCL2 in stem cell culture.

Story Source:

The above story is based on materials provided by RIKEN. Note: Materials may be edited for content and length.

The rest is here:
Pushing cells towards a higher pluripotency state

Recommendation and review posted by simmons

PUBLIC RELEASE DATE:

19-Jun-2014

Contact: Mary Beth O'Leary moleary@cell.com 617-397-2802 Cell Press

Stroke is a leading cause of death and disability in developed countries, and there is an urgent need for more clinically effective treatments. A study published by Cell Press June 19th in Stem Cell Reports reveals that simultaneous transplantation of neural and vascular progenitor cells can reduce stroke-related brain damage and improve behavioral recovery in rodents. The stem cell-based approach could represent a promising strategy for the treatment of stroke in humans.

"Our findings suggest that early cotransplantation treatment can not only replace lost cells, but also prevent further deterioration of the injured brain following ischemic stroke," says senior study author Wei-Qiang Gao of Shanghai Jiaotong University. "With the development of human embryonic and induced pluripotent stem cell technology, we are optimistic about the potential translation of our research into clinical use."

The most common kind of stroke, known as ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. Although a medicine called tissue plasminogen activator can break up blood clots in the brain, it must be given soon after the start of symptoms to work, and there are no other clinically effective treatments currently available for this condition. Stem cell transplantation represents a promising therapeutic strategy, but transplantation of either neural progenitor cells or vascular cells has shown restricted therapeutic effectiveness.

In the new study, Gao teamed up with colleagues at Shanghai Jiao Tong University, including Jia Li, Yaohui Tang, and Guo-Yuan Yang, to test whether cotransplantation of both neural and vascular precursor cells would lead to better outcomes. They induced ischemic stroke in rats and then simultaneously injected neural and vascular progenitor cells from mice into the stroke-damaged rat brains 24 hours later. The transplanted precursor cells turned into all major types of vascular and brain cells, including mature, functional neurons. The resulting vascular cells developed into microvessels, while the grafted neural cells produced molecules known to stimulate the growth of both neurons and vessels.

"This is the first study to use embryonic stem cell-derived vascular progenitor cells together with neural progenitor cells to treat ischemic stroke," Gao says. "These two types of progenitors generate nearly all types of brain cells, including endothelial cells, pericytes/smooth muscle cells, neurons, and astrocytes, resulting in better restoration of neurovascular units and better replacement of the lost cells in the stroke model. A previously reported cotransplantation approach published in the journal Stem Cells in 2009 (doi: 10.1002/stem.161) was limited because it did not use vascular precursor cells capable of turning into all major types of vascular cells important for recovery. Our findings here suggest that cotransplantation of the two types of cells that restore the neurovascular unit more effectively is a better approach for the treatment of ischemic stroke."

Two weeks after stroke, rats that had undergone cotransplantation showed less brain damage and improved behavioral performance on motor tasks compared with rats that had been treated with neural progenitor cells alone. "Our findings suggest that cotransplantation of neural and vascular cells is much more effective than transplantation of one cell type alone because these two cell types mutually support each other to promote recovery after stroke," Gao says.

###

See the original post:
Stem cell-based transplantation approach improves recovery from stroke

Recommendation and review posted by simmons

PUBLIC RELEASE DATE:

12-Jun-2014

Contact: Hannah Postles h.postles@sheffield.ac.uk 01-142-221-046 University of Sheffield

A time-lapse study of human embryonic stems cells has identified bottlenecks restricting the formation of colonies, a discovery that could lead to improvement in their use in regenerative medicine.

Biologists at the University of Sheffield's Centre for Stem Cell Biology led by Professor Peter Andrews and engineers in the Complex Systems and Signal Processing Group led by Professor Daniel Coca studied human pluripotent stem cells, which are a potential source of cells for regenerative medicine because they have the ability to produce any cell type in the body.

However, using these stem cells in therapies is currently hampered by the fact they can acquire genetic changes during prolonged culture which are non-random and resemble mutations in cancer cells.

Researchers used time-lapse imaging of single human embryonic stem cells to identify aspects of their behaviour that restrict growth and would be targets for mutations that allow cells to grow more efficiently.

Dr Ivana Barbaric, from the University of Sheffield's Department of Biomedical Science, said: "We study pluripotent stem cells, which have huge potential for use in regenerative medicine due to their ability to become any cell in the human body. A pre-requisite for this is maintaining large numbers of undifferentiated cells in culture. However, there are several obstacles such as cells tend to die extensively during culturing and they can mutate spontaneously. Some of these genetic mutations are known to provide stem cells with superior growth, allowing them to overtake the culture a phenomenon termed culture adaptation, which mimics the behaviour of cancer cells.

"In order for pluripotent stem cells to be used safely in regenerative medicine we need to understand how suboptimal culture conditions, for example culturing cells at low split ratios, affect the cells and can lead to culture adaptation."

The team's research combined the use of time-lapse microscopy, single-cell tracking and mathematical modelling to characterise bottlenecks affecting the survival of normal human embryonic stem cells and compared them with adapted cells.

See the original post:
Time-lapse study reveals bottlenecks in stem cell expansion

Recommendation and review posted by simmons

treatment available for autism spectrum disorder
After stem cell therapy treatment available for autism spectrum disorder parents of the child from London United Kingdom testifying most of the amazing improvements they saw after stem cell...

By: Neurogen Brain and Spine Institute

See the original post here:
treatment available for autism spectrum disorder - Video

Recommendation and review posted by simmons

PUBLIC RELEASE DATE:

16-Jun-2014

Contact: Colin Poitras colin.poitras@uconn.edu 860-486-4656 University of Connecticut

Scientists in the University of Connecticut's Technology Incubation Program have identified a novel approach to treating multiple sclerosis (MS) using human embryonic stem cells, offering a promising new therapy for more than 2.3 million people suffering from the debilitating disease.

The researchers demonstrated that the embryonic stem cell therapy significantly reduced MS disease severity in animal models and offered better treatment results than stem cells derived from human adult bone marrow.

The study was led by ImStem Biotechnology Inc. of Farmington, Conn., in conjunction with UConn Health Professor Joel Pachter, Assistant Professor Stephen Crocker, and Advanced Cell Technology (ACT) Inc. of Massachusetts. ImStem was founded in 2012 by UConn doctors Xiaofang Wang and Ren-He Xu, along with Yale University doctor Xinghua Pan and investor Michael Men.

"The cutting-edge work by ImStem, our first spinoff company, demonstrates the success of Connecticut's Stem Cell and Regenerative Medicine funding program in moving stem cells from bench to bedside," says Professor Marc Lalande, director of the UConn's Stem Cell Institute.

The research was supported by a $1.13 million group grant from the state of Connecticut's Stem Cell Research Program that was awarded to ImStem and Professor Pachter's lab.

"Connecticut's investment in stem cells, especially human embryonic stem cells, continues to position our state as a leader in biomedical research," says Gov. Dannel P. Malloy. "This new study moves us one step closer to a stem cell-based clinical product that could improve people's lives."

The researchers compared eight lines of adult bone marrow stem cells to four lines of human embryonic stem cells. All of the bone marrow-related stem cells expressed high levels of a protein molecule called a cytokine that stimulates autoimmunity and can worsen the disease. All of the human embryonic stem cell-related lines expressed little of the inflammatory cytokine.

Originally posted here:
Embryonic stem cells offer new treatment for multiple sclerosis

Recommendation and review posted by simmons

PUBLIC RELEASE DATE:

16-Jun-2014

Contact: David Ruth david@rice.edu 713-348-6327 Rice University

HOUSTON (June 16, 2014) How does a stem cell decide what path to take? In a way, it's up to the wisdom of the crowd.

The DNA in a pluripotent stem cell is bombarded with waves of proteins whose ebb and flow nudge the cell toward becoming blood, bone, skin or organs. A new theory by scientists at Rice University shows the cell's journey is neither a simple step-by-step process nor all random.

Theoretical biologist Peter Wolynes and postdoctoral fellow Bin Zhang set out to create a mathematical tool to analyze large, realistic gene networks. As a bonus, their open-access study to be published this week by the Proceedings of the National Academy of Sciences helped them understand that the process by which stem cells differentiate is a many-body problem.

"Many-body" refers to physical systems that involve interactions between large numbers of particles. Scientists assume these many bodies conspire to have a function in every system, but the "problem" is figuring out just what that function is. In the new work, these bodies consist not only of the thousands of proteins expressed by embryonic stem cells but also DNA binding sites that lead to feedback loops and other "attractors" that prompt the cell to move from one steady state to the next until it reaches a final configuration.

To test their tool, the researchers looked at the roles of eight key proteins and how they rise and fall in number, bind and unbind to DNA and degrade during stem cell differentiation. Though the interactions may not always follow a precise path, their general pattern inevitably leads to the desired result for the same reason a strand of amino acids will inevitably fold into the proper protein: because the landscape dictates that it be so.

Wolynes called the new work a "stylized," simplified model meant to give a general but accurate overview of how cell networks function. It's based on a theory he formed in 2003 with Masaki Sasai of Nagoya University but now takes into account the fact that not one but many genes can be responsible for even a single decision in a cellular process.

"This is what Bin figured out, that one could generalize our 2003 model to be much more realistic about how several different proteins bind to DNA in order to turn it on or off," Wolynes said.

Read more from the original source:
Many bodies prompt stem cells to change

Recommendation and review posted by Bethany Smith

Stratford, CT (PRWEB) June 24, 2014

Consumers should be aware of four things before buying skin care which are the ingredients, the formulation and the science to support the claims. The final thing they should notice are the results.

It had been several years since the anti-aging category had skyrocketed. Women are realizing that they can indeed skip the invasive procedures and reverse the signs of premature ageing skin with the help of a few bottles and jars. Theres just one catch, theyre just not bottles and jars; its Innarah. Innarah is the skin care collection that will change the way women feel about their skin.

Innarah is the first ever formulated skin care that works with the skins immune system.

Mr. Manzoor H. Jaffery, CEO Innarah Inc. has formulated a unique technology known as biofermentation. Mr. Jaffery perfected these fermented, anti-aging formulas and signature VenoDefense collection, which replicates the effects of snake venom using a botanical base with cutting edge ingredients such as Elk Antler Velvet, Ormus Gold, Plant Stem Cells and Marine Phytoplankton.

After being dissatisfied with so many skin care products on the market, Mr. Jaffery wanted something that really worked. Jaffery developed a process called Bioferm that is modelled on the ancient alchemic process called Nigredo, whose sole purpose is to transform the life force within matter. This process is actually different from other product formulations where the trick is their blending process. So, in essence, because Innarahs ingredients are fermented, there is no danger of the ingredients going through an oxidation process; plus, the result is a much more powerful cream.

As Jaffery explains, The ingredients are powerful, just like raw food. It helps with the skins own immune system. Many might dismiss this as hogwash, but listen to the science behind this for a bit. Because the skin is the largest organ in the body, and is the first line of defense in the immune system, its imperative to help protect it. This is why people recommend to eat daily fruits and vegetables.

Now, how can a skin care cream help with the immune system? It all has to do with the reticulation of Langerhans Cells, which are white blood cells generated in the bone marrow, Jaffery goes on to say. When they arrive at the epidermis, they develop small legs or dendrites, and automatically generate an immune response to the skin when they come into contact with ingredients they dont recognize. But ingredients that have been through the biofermentation process are readily accepted by these cells, so in essence Innarah acts as a bio catalyst.

Innarah is one of the few companies that offers an Oxygenated Crme that helps the healing of adult acne, cold sores, hyperpigmentation and other skin issues. Using Innarah products also aid the skin by diffusing and removing under eye puffiness and inflammation.

Innarah is for any skin color or gender and is recommended for people between 25-85 years old. Innarah is for that glow from-within associated with youth.

Read the rest here:
The Discovery of a Unique Skincare System Which Acts as Food for the Skin and Absorb Immediately Reducing the ...

Recommendation and review posted by Bethany Smith

Alzheimer #39;s Disease Prevention and Treatment
http://www.placidway.com/subtreatment-detail/treatment,31,subtreatment,256.html/Alzheimers-Disease-Stem-Cell-Therapy--Treatment-Abroad - Watch this educational video about Alzheimer #39;s disease...

By: placidways

See original here:
Alzheimer's Disease Prevention and Treatment - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

17-Jun-2014

Contact: Vera Siegler vera.siegler@tum.de 49-892-892-2731 Technische Universitaet Muenchen

This news release is available in German.

The cells of the human immune system are created from special stem cells in the bone marrow. In diseases affecting the bone marrow, such as leukemia, the degenerate cells must be destroyed using radiation or chemotherapy. Subsequently, the hematopoietic system has to be replaced with stem cells from the blood of a healthy donor. Because of the resulting temporary weakening of the immune system, patients are more exposed to viruses that would normally be warded off.

The cytomegalovirus (CMV), which can cause serious damage to lungs or liver in persons with a weakened defense, poses a major clinical problem. In healthy human beings, a CMV infection will usually not produce any symptoms, since the virus is kept at bay by specific immune cells. In their work, the scientists were able to demonstrate that the transfer of just a few specific immune cells is sufficient to protect the recipient with the weakened immune system against infections. To do this, they used T cells that can recognize and kill specific pathogens.

Tested in an animal model

Dr. Christian Stemberger, first author of the study, and his colleagues, first isolated T cells from the blood of healthy donor mice. These immune cells were directed against molecular elements of a bacterial species which normally causes severe infections in animals. The T cells were then transferred to recipient mice that, due to a genetic modification, could no longer produce immune cells of their own similarly to patients suffering from leukemia.

Following the T cell transfer, the researchers infected the treated recipient mice with the bacteria. The results showed that the animals now have effective immune protection against the pathogens, preventing them from becoming ill. "The most astonishing result was that the offspring cells of just one transferred donor cell were enough to completely protect the animals," Christian Stemberger explains.

Successfully used in patients

Read more from the original source:
Promising T cell therapy

Recommendation and review posted by Bethany Smith